Objectives To investigate the knowledge and views of a range of healthcare professionals (consultant paediatricians, general practitioners (GPs), community pharmacists and paediatric nurses) regarding the use of unlicensed/off-label medicines in children and the participation of children in clinical trials. Methods A regional study in which a survey instrument with 39 items was issued to 500 randomly selected GPs, all community pharmacists (n=512), 50 hospital consultants and 150 paediatric nurses in Northern Ireland. Results Approximately half (46.5%) of the 1,212 healthcare professionals approached responded to the questionnaire. The majority of respondents indicated their familiarity with the term unlicensed (82.9%) or off-label (58.6%) prescribing with the most frequently quoted reason for such prescribing being younger age (33.6%). Apart from community pharmacists, most respondents reported having gained their knowledge through personal experience. Even though a large percentage of respondents expressed concerns about the safety (77.8%) or efficacy (87.9%) of unlicensed/off-label prescribing in children, only 30.7% reported informing parents/guardians of these concerns on the use of such medicines in children. In addition, only 56% of respondents believed that unlicensed/off-label medicines should undergo clinical trials in children. Overall, 28.4% of respondents (20.1% of GPs, 41.4% of community pharmacists, 27.7% of paediatric nurses and 94% of consultant paediatricians) indicated their willingness to be actively involved in, and recruit their patients for paediatric clinical research. Conclusion The use of unlicensed and off-label medicines remains a major issue in paediatric medicine. Until such times as more licensed medicines are available for children, clear guidance should be developed to allow consistency in practice across the spectrum of healthcare professionals who are involved with such medicines in their routine practice.
Introduction
Even though it is well documented that children are not small adults, [1, 2] , many of the medicines currently used to treat children are based upon extrapolation of adult data [3, 4] , primarily due to the fact that many medicines are only tested in and subsequently licensed for adult patients [5] . A review of 30 studies carried out between 1984 and 2004 revealed that 11-37% of drugs prescribed to children in the community setting, 16-62% prescribed in general paediatric wards and up to 80% prescribed in neonatal intensive care units are either unlicensed or used in an off-label manner (i.e., prescribed outside their product license with respect to age, dose, route of administration or indication) [6] . Despite this wide-spread use of unlicensed/off-label medicines in children, only 40% of general practitioners (GPs) admit to unlicensed/ off-label prescribing [7] . An additional study involving a cohort of 95 French paediatricians showed that 92% of the participating paediatricians did not recognise the off-label status of the medicines they prescribed [8] , while another study conducted recently in four Italian paediatric hospitals found a discordance between the existing prescribing behaviour and physicians' perceptions of off-label prescribing. This was explained by the fact that paediatricians did not consider some of the most commonly prescribed drugs in their everyday practice as being off-label [9] . Off-label/ unlicensed prescribing for children is a global problem. However, recent major research initiatives in the USA and Europe are beginning to address the issue of the need for a greater evidence base for the safe and effective use of medicines in this age group [10] .
In the meantime, off-label/unlicensed prescribing often represents the most rational use of medicines if no approved alternatives for children with comparable benefit-risk ratio are available [10] . In most cases, some data are available on paediatric use, ranging from scarce to adequate for market authorisation, but even when adequate data are available, these have not been submitted by a pharmaceutical company to the regulatory authorities for evaluation, and no age appropriate formulations are available [10] .
There is growing concern among healthcare professionals about the safety and efficacy of unlicensed/off-label medicine use in children, particularly due to the lack of long-term safety and efficacy data in this vulnerable group and due to evidence suggesting an increased risk of adverse drug reactions (ADRs) and treatment failure [11] [12] [13] . The ethical obligation of providing the best available treatment to children coupled with a lack of availability of licensed paediatric products highlight the need for an increased number of clinical trials in children. Performing such trials, however, requires that special attention be paid to the various challenges associated with clinical trials involving paediatric populations [14] .
To date, limited data have been published on the views and experiences of different healthcare professionals on these matters. The aim of the present study was, therefore, to investigate the knowledge and views of a wide range of healthcare professionals (including consultant paediatricians, GPs, community pharmacists and paediatric nurses) regarding the use of unlicensed/off-label medicines in children and the participation of children in clinical trials.
Methods
A survey instrument comprising 39 questions (Appendix 1) was designed after an extensive review of the literature. The questionnaire focused primarily on the use of unlicensed and off-label medicines in children and consisted of five sections addressing different topics of interest together with a separate section on participant details and demographics (to allow examination of variability in responses according to participant characteristics). The first section focused on the experiences and views of healthcare professionals regarding the use of unlicensed and off-label medicines in children, while the second section focused on parental involvement in decision-making regarding the medicine being prescribed for their child. The third section addressed the information sources that healthcare professionals use when prescribing, dispensing and administering unlicensed/ off-label medicines to children. The fourth section focused on paediatric clinical trials, while the final section focused on dose-related issues when prescribing unlicensed and offlabel medicines in children. Information (definitions and examples) regarding the unlicensed/off-label use of medicines in children was provided as an integral part of the questionnaire to guide respondents who were not familiar with the terminology.
Prior to the full study, the questionnaire was piloted using a small number of healthcare professionals (n=20) (pharmacists and doctors); these results were not included in the final analysis. The respondents indicated that the questionnaire was clear and easy to understand. The questionnaire was then posted to GPs, community pharmacists and hospital-based paediatric nurses and e-mailed to consultant paediatricians across Northern Ireland. The questionnaires were mailed to 500 randomly selected GPs (http://allen.netcom.co.uk/Sampling.htm) and all community pharmacists (n=512). The recipients were allowed 4 weeks to return the completed questionnaire. A letter was also sent to the paediatric nursing units of all hospitals in Northern Ireland in which the head of each ward was asked to reply if he/she was willing to have the nursing staff of that unit take part in this study, and if this were the case, how many questionnaires would be required. Questionnaires (n=150) were subsequently sent to those units which agreed to take part in the study, with a 4-week window to complete the questionnaire.
Finally, questionnaires were e-mailed to all consultant paediatricians in Northern Ireland (n=50), with the request to complete and return the questionnaire within 4 weeks. This survey was not sent to hospital pharmacists due to the small number of specialist paediatric pharmacists in Northern Ireland. Following data collection, responses were coded and entered into a customised database in SPSS, ver. 15 (SPSS, Chicago, IL) for statistical analyses (chi-square test and sign tests). Consultation with the Office of Research Ethics Committees in Northern Ireland (ORECNI) confirmed that the study did not require formal review by the National Health Service (NHS) ethics committee. The study did, however, receive ethical approval from the School of Pharmacy, Queen's University Belfast Research Ethics Committee.
Results

Demographics
Of the 1,212 distributed questionnaires, 563 (46.5%) were returned completed and 32 uncompleted. A total of 59.8% of GPs, 32.8% of community pharmacists, 72.0% of consultant paediatricians and 43.3% of paediatric nurses replied. The majority of respondents were female (59.2%) and ranged in age from 20 to 40 years (60.8%).
Knowledge and views on unlicensed/off-label medicines
The majority of respondents (467; 82.9%) indicated that prior to receiving the questionnaire they were familiar with the term unlicensed medicines, while 330 (58.6%) indicated they were familiar with the term off-label medicines. There was a significant difference among the different sectors of healthcare professionals with respect to their familiarity with unlicensed/off-label prescribing (P<0.05), with community pharmacists being most familiar with the term unlicensed medicines (93%) and consultant paediatricians being most familiar with the term off-label medicines (83.3%). When asked how they became familiar with the terminology of unlicensed and off-label medicines, 51.7% of respondents said they had gained their knowledge through their professional experience rather than through undergraduate (24%) or postgraduate (16.5%) training. A separate analysis of data on community pharmacists, however, indicated that these individuals had gained their knowledge mainly through their undergraduate studies (50.0%) rather than through their experience (39.0%) or postgraduate studies (33.1%), with these data being significantly different (P<0.05) from corresponding results for other groups.
Approximately one-quarter (24.5%) and one-third (31%) of the respondents reported actually prescribing, dispensing or administering unlicensed and off-label medicines, respectively, to children in their practice during the 4 weeks that preceded answering the questionnaire. The reasons given for off-label prescribing were younger age (33.6%), lower than recommended dose (30.7%), higher than recommended dose (29.1%), different indication (29.1%) or different route of administration (24.2%) from that of the licensed product. No significant differences in the perceived reasons for off-label prescribing were found among the different healthcare professionals (P>0.05). In addition, the majority of respondents reported infants (1-23 months of age) to be most likely to receive unlicensed (40.9%) or offlabel (35.0%) medicines. In comparison, children aged 2-11 years and children aged 12-18 years were, according to the respondents, less likely to receive unlicensed (22.1%) or off-label (33.0%) medicines (Table 1) .
When asked to rank the most important ways by which unlicensed and off-label medicine use in children could be reduced, the majority of respondents (60%) ranked making more appropriate formulations available for younger children as a 'very important' approach, followed by increasing clinical trials for new drugs (38.5%) and, finally, increasing clinical trials for existing drugs (28.6%). There were no significant differences between different groups of healthcare professionals with regards to this subject (P>0.05).
Views on the safety and efficacy of unlicensed/off-label medicines The majority of respondents had major and/or minor concerns regarding the safety (77.8%) and the efficacy (87.9%) of unlicensed and off-label medicine use in children. Safety and efficacy concerns were more frequently raised by pharmacists and GPs than by consultant paediatricians and paediatric Fig. 1 
for categories).
When asked about which is more problematic with regard to safety, approximately one-quarter of respondents (26.8%) thought that the use of unlicensed medicines was more problematic that the use of off-label medicines. However, almost half of the respondents (48.5%) felt that the use of unlicensed and off-label medicines is equally problematic with regard to safety.
Dosing-related issues and information sources
The vast majority (93.4%) of respondents reported that they double-checked doses of medicines used in children if a calculation was required in deciding on the dose. Interestingly, 78.3% of respondents had come across a dosing error in a paediatric prescription in their professional practice.
Almost half of respondents (43.7%) felt that licensing more medicines for use in children would decrease dosing errors in children. However, GPs and community pharmacists had stronger views than consultants and paediatric nurses on this issue (47.0 and 55.5% vs. 8.3 and 18.5%, respectively). When asked about the various information sources they used when dealing with medicines in children, respondents reported that the British National Formulary for Children (BNFc) was the most commonly used source, followed by the British National Formulary (BNF) ( Table 2 ). In addition, they stated that, of all sources, the BNFc contained the most appropriate information to support their practice.
Communication with parents and guardians
Although 85.4% of respondents agreed that parents/guardians should be told when an unlicensed or off-label medicine was prescribed for their children, only 30.7% of respondents reported informing parents and guardians when such medicines were used. Only 1.1% of respondents said that they request written consent from parents or guardians, while 45.1% said that they request verbal consent when informing parents about the unlicensed/off-label use of medicines. As a group, GPs most frequently claimed informing parents (41.9%) and asking for verbal consent (39.3%).
Overall, respondents felt that parents should be informed by the doctor (95.7%), pharmacist (2.3%) or nurse (0.5%) within the hospital setting, while in primary care, the providers of the information were selected in the order doctor (94.0%) and community pharmacist (4.6%).
Clinical trials in children
When asked about the need for more paediatric clinical trials to address the issue of unlicensed/off-label medicine use, 56% of the respondents believed that medicines used in an unlicensed/ off-label fashion should undergo clinical trials in children. This percentage was reasonably consistent for all healthcare professional groups (i.e., 55.6, 52.7, 64.9, 49.3%; same categories as Fig. 1 ). Moreover, approximately half of the respondents (54.7%) agreed that pharmaceutical companies should be required to carry out research on new medicines in children. However, only 28.4% of respondents indicated that they would be willing to be actively involved in and to recruit their own patients for paediatric clinical research. Among the healthcare profession groups responding, consultant paediatricians (94.4%) reported the most willingness to help with clinical trials (Fig. 2) .
Respondents were also asked if they would allow their own children to participate in clinical trials. No significant difference was found between those who had children of their own and those who did not (P>0.05; chi-square test). However, this willingness was influenced by the assumed health status of the child and whether the medicine was new or an existing medicine used in unlicensed/off-label manner (Fig. 3) .
Discussion
The lack of alternate medicines for children that have received government approval and the lack of paediatric formulations even if data on paediatric pharmacology of a drug are available mean that off-label and unlicensed prescribing continues to be a necessary feature of contemporary paediatric practice. To the best of our knowledge, this is the first study that contemporaneously assesses a range of healthcare professionals (consultant paediatricians, GPs, community pharmacists and paediatric nurses) in terms of their levels of knowledge and views on the use of unlicensed/off-label medicines in children; 1,212 healthcare professionals throughout Northern Ireland were approached in this survey, with approximately half of them responding.
The majority of consultants, GPs and community pharmacists were familiar with the concept of unlicensed/ off-label prescribing. The most commonly reported reason for such prescribing was 'use at a younger age than recommended'. This finding was consistent with the results of earlier studies examining views/attitudes of GPs and community pharmacists in the UK [7, 15] and matches actual data collected in a survey of UK hospital-based prescribing [16] . In the community setting in the UK [17] , however, 'lower dose than recommended' has been shown to be the most frequent cause for off-label prescribing, while younger age than recommended is amongst the least frequently reported reason for this mode of medicine use. With the exception of pharmacists, most respondents (including GPs) reported having gained their knowledge through personal experience rather than via their undergraduate or postgraduate training. This situation is similar to that reported in an earlier study [7] . This reliance on personal experience highlights a significant deficiency in current healthcare undergraduate and postgraduate education.
An interesting result of our survey was that a very low percentage of healthcare professionals inform parents or seek their consent when an unlicensed or off-label medicine is prescribed, dispensed or administered to a child. This finding coincides with that reported in a recent study performed in Germany showing a limited and surprisingly low knowledge of off-label prescribing among parents of chronically ill children [18] . In an earlier public opinion survey carried out in Northern Ireland, a significant percentage of parents/ guardians reported that they would refuse the use of such medicines or ask for the prescription of a licensed alternative if they were informed about the unlicensed use of medicines in their child. In addition, the majority of participants in that latter study (92.1%) felt that parents should be told if their child was being prescribed a medicine that had not been fully studied or licensed in children [19] .
A large number of respondents expressed concerns regarding the safety and efficacy of unlicensed/off-label medicines and reported cases of treatment failure and side effects of such agents during their practice. Paediatric nurses were the least concerned about safety/efficacy issues when compared with the other groups of healthcare professionals. This was attributed to this group being very accustomed to treating large numbers of children, many of whom will receive medicines outside the licensed recommendations. Another interesting result was the fact that the reported experiences of treatment failure in this study were higher than experiences of ADRs following the use of unlicensed/off-label medicines in children. This finding may reflect clinicians being overly cautious in using appropriately high doses and is supported by the fact that experiences of treatment failures were associated with 'lower than recommended' dosing being identified as the main reason for off-label use.
The vast majority of respondents (93.4%) claimed that they double-checked the doses of medicines used in children when a dosage calculation is required. In doing this, more than three-quarters of respondents reported that they had come across a dosing error in a paediatric prescription in their professional practice. Concern about this high incidence of error detection is compounded by the fact that the literature shows that the potential for medication errors in children receiving unlicensed/off-label medicines to cause harm is threefold higher than that of similar errors in adults [20] .
Surprisingly, only half of the respondents believed that unlicensed/off-label medicines should undergo clinical trials in children despite their concerns about the safety and efficacy of these medicines. These findings are consistent with the results of a recent survey of the attitudes of hospital-based paediatricians [21] in Scotland but in contrast with those expressed by Scottish GPs who were more convinced of the need for appropriate clinical trials in children [7] . In order to conduct such clinical trials there needs to be an increased willingness of both clinicians and parents to become involved in this type of research. In the study reported here, such willingness was found to be very much higher among consultant paediatricians than in the other professional groups (Fig. 2) . It has been shown that the willingness of parents to consent for their children to take part in clinical trials is associated with the worsening of the child's health status and when children can directly benefit from the clinical research [18, 19] . The findings of Fig. 3 Respondents' (parents vs. non-parents) responses regarding enrolling their own child in a clinical trial based on their child's health status and whether the medicine to be tested was a new medicine or an existing medicine used in an unlicensed or off-label manner. GH Child in good health, BH child has a medical condition for which the medicine could be beneficial, NM new medicine which has not received a license for adult use, EM medicine which is licensed for adult use our study showed that this also holds true for healthcare professionals who are themselves parents. Overall, the results of the survey reported here indicated that much remains to be achieved in the area of both managing off-label and unlicensed medicine use and in creating an environment in which research in children aimed at improving the evidence base is integrated into routine practice.
